Cargando…

Anatomical sites (Takasaki’s segmentation) predicts the recurrence-free survival of hepatocellular carcinoma

BACKGROUND: Until now, several classification staging system and treatment algorithm for hepatocelluar carcinoma (HCC) has been presented. However, anatomical location is not taken into account in these staging systems. The aim of this study is to investigate whether anatomical sites could predict t...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Wei, Wang, Li, Hu, Beiyuan, Tian, Huan, Xiao, Cuicui, Luo, Huanxian, Yang, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176619/
https://www.ncbi.nlm.nih.gov/pubmed/34082743
http://dx.doi.org/10.1186/s12893-021-01275-3
_version_ 1783703288636506112
author Qin, Wei
Wang, Li
Hu, Beiyuan
Tian, Huan
Xiao, Cuicui
Luo, Huanxian
Yang, Yang
author_facet Qin, Wei
Wang, Li
Hu, Beiyuan
Tian, Huan
Xiao, Cuicui
Luo, Huanxian
Yang, Yang
author_sort Qin, Wei
collection PubMed
description BACKGROUND: Until now, several classification staging system and treatment algorithm for hepatocelluar carcinoma (HCC) has been presented. However, anatomical location is not taken into account in these staging systems. The aim of this study is to investigate whether anatomical sites could predict the postoperative recurrence of HCC patients. METHODS: 294 HCC patients were enrolled in this retrospective study. A novel score classification based on anatomical sites was established by a Cox regression model and validated in the internal validation cohort. RESULTS: HCC patients were stratified according to the novel score classification into three groups (score 0, score 1–3 and score 4–6). The predictive accuracy of the novel recurrence score for HCC patients as determined by the area under the receiver operating characteristic curves (AUCs) at 1, 3, and 5 years (AUCs 0.703, 0.706, and 0.605) was greater than that of the other representative classification systems. These findings were supported by the internal validation cohort. For patients with Barcelona Clinic Liver Cancer (BCLC) 0 and A stage, our data demonstrated that there was no significant difference in recurrence-free survival (RFS) between patients with score 0 and liver transplantation recipients. Additionally, we introduced this novel classification system to guide anatomical liver resection for centrally located liver tumors. CONCLUSION: The novel score classification may provide a reliable and objective model to predict the RFS of HCC after hepatic resection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12893-021-01275-3.
format Online
Article
Text
id pubmed-8176619
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81766192021-06-04 Anatomical sites (Takasaki’s segmentation) predicts the recurrence-free survival of hepatocellular carcinoma Qin, Wei Wang, Li Hu, Beiyuan Tian, Huan Xiao, Cuicui Luo, Huanxian Yang, Yang BMC Surg Research Article BACKGROUND: Until now, several classification staging system and treatment algorithm for hepatocelluar carcinoma (HCC) has been presented. However, anatomical location is not taken into account in these staging systems. The aim of this study is to investigate whether anatomical sites could predict the postoperative recurrence of HCC patients. METHODS: 294 HCC patients were enrolled in this retrospective study. A novel score classification based on anatomical sites was established by a Cox regression model and validated in the internal validation cohort. RESULTS: HCC patients were stratified according to the novel score classification into three groups (score 0, score 1–3 and score 4–6). The predictive accuracy of the novel recurrence score for HCC patients as determined by the area under the receiver operating characteristic curves (AUCs) at 1, 3, and 5 years (AUCs 0.703, 0.706, and 0.605) was greater than that of the other representative classification systems. These findings were supported by the internal validation cohort. For patients with Barcelona Clinic Liver Cancer (BCLC) 0 and A stage, our data demonstrated that there was no significant difference in recurrence-free survival (RFS) between patients with score 0 and liver transplantation recipients. Additionally, we introduced this novel classification system to guide anatomical liver resection for centrally located liver tumors. CONCLUSION: The novel score classification may provide a reliable and objective model to predict the RFS of HCC after hepatic resection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12893-021-01275-3. BioMed Central 2021-06-03 /pmc/articles/PMC8176619/ /pubmed/34082743 http://dx.doi.org/10.1186/s12893-021-01275-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Qin, Wei
Wang, Li
Hu, Beiyuan
Tian, Huan
Xiao, Cuicui
Luo, Huanxian
Yang, Yang
Anatomical sites (Takasaki’s segmentation) predicts the recurrence-free survival of hepatocellular carcinoma
title Anatomical sites (Takasaki’s segmentation) predicts the recurrence-free survival of hepatocellular carcinoma
title_full Anatomical sites (Takasaki’s segmentation) predicts the recurrence-free survival of hepatocellular carcinoma
title_fullStr Anatomical sites (Takasaki’s segmentation) predicts the recurrence-free survival of hepatocellular carcinoma
title_full_unstemmed Anatomical sites (Takasaki’s segmentation) predicts the recurrence-free survival of hepatocellular carcinoma
title_short Anatomical sites (Takasaki’s segmentation) predicts the recurrence-free survival of hepatocellular carcinoma
title_sort anatomical sites (takasaki’s segmentation) predicts the recurrence-free survival of hepatocellular carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176619/
https://www.ncbi.nlm.nih.gov/pubmed/34082743
http://dx.doi.org/10.1186/s12893-021-01275-3
work_keys_str_mv AT qinwei anatomicalsitestakasakissegmentationpredictstherecurrencefreesurvivalofhepatocellularcarcinoma
AT wangli anatomicalsitestakasakissegmentationpredictstherecurrencefreesurvivalofhepatocellularcarcinoma
AT hubeiyuan anatomicalsitestakasakissegmentationpredictstherecurrencefreesurvivalofhepatocellularcarcinoma
AT tianhuan anatomicalsitestakasakissegmentationpredictstherecurrencefreesurvivalofhepatocellularcarcinoma
AT xiaocuicui anatomicalsitestakasakissegmentationpredictstherecurrencefreesurvivalofhepatocellularcarcinoma
AT luohuanxian anatomicalsitestakasakissegmentationpredictstherecurrencefreesurvivalofhepatocellularcarcinoma
AT yangyang anatomicalsitestakasakissegmentationpredictstherecurrencefreesurvivalofhepatocellularcarcinoma